D-Glutamine
- Generic Name
- D-Glutamine
- Brand Names
- Endari
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O3
- CAS Number
- 5959-95-5
- Unique Ingredient Identifier
- 63HB36CA2Y
- Background
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
- Indication
Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older .
- Associated Conditions
- Osteoporosis, Acute Complications of Sickle Cell Disease
- Associated Therapies
- -
Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta From the Market
Pfizer withdraws Oxbryta (voxelotor) for sickle cell disease from all markets due to imbalance in vaso-occlusive crises and fatal events, discontinuing all clinical trials and expanded access program.
Pfizer's Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer withdraws sickle cell drug Oxbryta from global market due to safety concerns, leaving patients and advocates scrambling. The decision follows EMA review highlighting increased vaso-occlusive crisis cases. Pfizer pauses ongoing clinical trials and shuts down expanded access programs. The FDA advises against prescribing Oxbryta and recommends alternative treatments.
Related Clinical Trials:
Pfizer to pull sickle cell drug from market, shut down trials
Pfizer is withdrawing Oxbryta, a sickle cell disease drug, due to safety concerns, leading to an imbalance of deaths and vaso-occlusive crises. The European Medicines Agency recommended suspending its clearance. Pfizer acquired Oxbryta through its purchase of Global Blood Therapeutics in 2022, with Oxbryta generating $92 million in revenue in Q2 2024. Pfizer continues to develop other sickle cell treatments, including inclacumab and osivelotor in Phase 3. Patients currently on Oxbryta should consult their doctors for alternatives.
Native Fiber Review: Does It Help Relieve Stuck Stool and Improve Gut Health?
NativePath Native Fiber is a dietary supplement supporting blood sugar and metabolism with organic ingredients like baobab, soluble and insoluble fiber, and L-glutamine. It aids in digestion, weight management, and immune support, available at competitive prices with free shipping. While not FDA-approved, it adheres to Good Manufacturing Practices and has positive user feedback.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath